Canadian pharmaceutical company Apotex Health Corp (TSX:APTX) announced on Monday the US launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version of Pfizer's INLYTA, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Renal cell carcinoma is the most common type of kidney cancer in adults and accounts for approximately 90% of kidney cancer diagnoses. Axitinab Tablets provide an additional FDA-approved treatment option for appropriate patients with advanced RCC following failure of one prior systemic therapy.
Axitinib Tablets are supplied as 1 mg tablets in bottles of 180 (NDC 60505-4427-8) and 5 mg tablets in bottles of 60 (NDC 60505-4428-6).
Upsher-Smith launches Glatiramer Acetate Injection generic
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings